Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Zai Lab Ltd (ZLAB)

Zai Lab Ltd (ZLAB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,572,388
  • Shares Outstanding, K 58,110
  • Annual Sales, $ 12,990 K
  • Annual Income, $ -195,070 K
  • 60-Month Beta 1.16
  • Price/Sales 371.20
  • Price/Cash Flow N/A
  • Price/Book 18.40
Trade ZLAB with:

Options Overview

Details
  • Implied Volatility 77.44%
  • Historical Volatility 48.45%
  • IV Percentile 80%
  • IV Rank 12.48%
  • IV High 302.60% on 03/16/20
  • IV Low 45.35% on 07/09/20
  • Put/Call Vol Ratio 4.00
  • Today's Volume 30
  • Volume Avg (30-Day) 132
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 1,169
  • Open Int (30-Day) 808

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.68
  • Growth Rate Est. (year over year) +147,011.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
144.10 +2.36%
on 02/26/21
187.46 -21.32%
on 02/10/21
-17.86 (-10.80%)
since 02/01/21
3-Month
105.37 +39.98%
on 12/08/20
193.54 -23.79%
on 01/20/21
+38.57 (+35.41%)
since 12/01/20
52-Week
43.06 +242.55%
on 03/16/20
193.54 -23.79%
on 01/20/21
+92.53 (+168.33%)
since 02/28/20

Most Recent Stories

More News
3 Chinese Stocks Outperforming NIO in 2021

Even though NIO (NIO) has delivered spectacular returns over the past year, Tencent (TME), Bilibili (BILI), and Zai Lab (ZLAB) have outperformed the stock so far this year. Based on growing market demand...

TME : 26.27 (+2.14%)
BILI : 131.50 (+4.39%)
ZLAB : 147.50 (-0.01%)
3 Lesser-Known Biotech Stocks that are Surging

The biotechnology sector has been the focus of investors since the outbreak of the COVID-19 pandemic. Initially, all eyes were on accurate COVID-19 testing, followed by an anxious wait for vaccines. The...

BGNE : 320.00 (-2.95%)
ALNY : 148.10 (+1.03%)
ZLAB : 147.50 (-0.01%)
Why Chinese Stock Bilibili is up More than 300% in 2020

Bilibili Inc.’s (BILI) entertainment platform enables its users to consume and create content. The company has quickly become quite popular as its user base has increased exponentially due to the coronavirus....

BILL : 167.09 (+1.26%)
BIDU : 298.00 (+5.13%)
VIPS : 37.73 (+1.10%)
ZLAB : 147.50 (-0.01%)
Qiming's Portfolio Company Antengene Lists on Main Board of HKEX

, /PRNewswire/ -- Qiming's portfolio company Antengene (SEHK: 6996) officially listed on the Main Board of The Stock Exchange of Hong Kong Limited today. The issue price is per share; the stock opens...

BILI : 131.50 (+4.39%)
ZLAB : 147.50 (-0.01%)
SDGR : 107.00 (+4.41%)
Inmagene Biopharmaceuticals closed $21 million Series B financing, making the total raised to date over $40 million

, /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene"), announced today that it had closed a Series B financing, led by Vertex Ventures China, and co-invested by Panacea Venture, Kunlun Capital,...

ZLAB : 147.50 (-0.01%)
IMAB : 59.19 (+1.21%)
Zai Lab Announces Closing of Hong Kong Secondary Listing

Zai Lab Limited ("Zai Lab" or the "Company") (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced listing of its ordinary shares on the Main Board of The Stock Exchange...

ZLAB : 147.50 (-0.01%)
Zai Lab Announces Pricing of Hong Kong Secondary Listing

Zai Lab Limited ("Zai Lab" or the "Company") (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced the pricing of the Hong Kong secondary listing (the "Hong Kong Secondary...

ZLAB : 147.50 (-0.01%)
Zai Lab Launches Hong Kong Secondary Listing

Zai Lab Limited ("Zai Lab" or the "Company") (NASDAQ:ZLAB), an innovative commercial stage biopharmaceutical company, today announced the launch of its Hong Kong public offering (the "Hong Kong Public...

ZLAB : 147.50 (-0.01%)
Zai Lab Announces Clinical Data to be Presented at ESMO Virtual Congress 2020

Zai Lab Limited ("Zai Lab") (NASDAQ: ZLAB), an innovative commercial-stage biopharmaceutical company, today announced that detailed clinical data from the NORA Phase 3 study of niraparib have been accepted...

ZLAB : 147.50 (-0.01%)
Zai Lab Announces Upcoming Participation in September Conferences

Zai Lab Limited ("Zai Lab") (NASDAQ: ZLAB), an innovative commercial-stage biopharmaceutical company, today announced that Dr. Samantha Du, Founder, Chairwoman and Chief Executive Officer of Zai Lab, will...

ZLAB : 147.50 (-0.01%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Zai Lab Ltd is a biopharmaceutical company. It focused on medicines for cancer, autoimmune and infectious diseases primarily in China. The company's product pipeline consists of ZL-2306, ZL-2401, ZL-2301, ZL-3101, ZL-2302 and ZL-1101 which are in clinical stage. Zai Lab Ltd is based in Pudong, China....

See More

Key Turning Points

3rd Resistance Point 157.68
2nd Resistance Point 154.28
1st Resistance Point 150.90
Last Price 147.50
1st Support Level 144.12
2nd Support Level 140.72
3rd Support Level 137.34

See More

52-Week High 193.54
Last Price 147.50
Fibonacci 61.8% 136.06
Fibonacci 50% 118.30
Fibonacci 38.2% 100.54
52-Week Low 43.06

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar